Andrea Wittig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea Wittig has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Raymond L. Moss
ESE Unit, Institute for Energy and Transport, Joint Research Centre, European Commission, Petten, The Netherlands
4 shared publicationsWolfgang A.G. Sauerwein
Department of Radiation Oncology, University Hospital Essen, NCTeam, University Duisburg-Essen, Essen, Germany
4 shared publicationsChristian Kriegeskotte
2 shared publicationsHeinrich F. Arlinghaus
2 shared publicationsKarl‐Heinz Jöckel
Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University Duisburg‐Essen, Essen, Germany
2 shared publicationsKlaas Appelman
Nuclear Research and consultancy Group (NRG), Petten, The Netherlands
2 shared publications
Latest Publications
- 1 June 2014
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 88, 46-49
Glioblastoma, brain metastases and soft tissue sarcoma of extremities: Candidate tumors for BNCT
- 1 June 2014
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 88, 46-49
Glioblastoma, brain metastases and soft tissue sarcoma of extremities: Candidate tumors for BNCT
- 1 October 2009
- Published by Radiation Research Society in Radiation Research
- Vol. 172 (4) , 493-499
Biodistribution of10B for Boron Neutron Capture Therapy (BNCT) in a Mouse Model after Injection of Sodium Mercaptoundecahydro-closo-dodecaborate and l-para-Boronophenylalanine
In boron neutron capture therapy, the absorbed dose from the (10)B(n,alpha)(7)Li reaction depends on the (10)B concentration and (10)B distribution in the irradiated volume. Thus compounds used in BNCT should have tumor-specific uptake and low accumulation in normal tissues. This study compares in a mouse model the (10)B uptake in different organs as delivered by l-para-boronophenylalanine (BPA, 700 mg/kg body weight, i.p.) and/or sodium mercaptoundecahydro-closo-dodecaborate (BSH, 200 mg/kg body weight, i.p). After BSH injection, the (10)B concentration was high in kidneys (20 +/- 12 microg/g) and liver (20 +/- 12 microg/g) but was low in brain (1.0 +/- 0.8 microg/g) and muscle (1.9 +/- 1.2 microg/g). After BPA injection, the (10)B concentration was high in kidneys (38 +/- 25 microg/g) and spleen (17 +/- 8 microg/g) but low in brain (5 +/- 3 microg/g). After combined BPA and BSH injection, the effect on the absolute (10)B concentration was additive in all organs. The ratio of the (10)B concentrations in tissues and blood differed significantly for the two compounds depending on the compound combination, which implies a different uptake profile for normal organs.
- 1 October 2009
- Published by Radiation Research Society in Radiation Research
- Vol. 172 (4) , 493-499
Biodistribution of10B for Boron Neutron Capture Therapy (BNCT) in a Mouse Model after Injection of Sodium Mercaptoundecahydro-closo-dodecaborate and l-para-Boronophenylalanine
In boron neutron capture therapy, the absorbed dose from the (10)B(n,alpha)(7)Li reaction depends on the (10)B concentration and (10)B distribution in the irradiated volume. Thus compounds used in BNCT should have tumor-specific uptake and low accumulation in normal tissues. This study compares in a mouse model the (10)B uptake in different organs as delivered by l-para-boronophenylalanine (BPA, 700 mg/kg body weight, i.p.) and/or sodium mercaptoundecahydro-closo-dodecaborate (BSH, 200 mg/kg body weight, i.p). After BSH injection, the (10)B concentration was high in kidneys (20 +/- 12 microg/g) and liver (20 +/- 12 microg/g) but was low in brain (1.0 +/- 0.8 microg/g) and muscle (1.9 +/- 1.2 microg/g). After BPA injection, the (10)B concentration was high in kidneys (38 +/- 25 microg/g) and spleen (17 +/- 8 microg/g) but low in brain (5 +/- 3 microg/g). After combined BPA and BSH injection, the effect on the absolute (10)B concentration was additive in all organs. The ratio of the (10)B concentrations in tissues and blood differed significantly for the two compounds depending on the compound combination, which implies a different uptake profile for normal organs.
- Open Access
- 10 July 2009
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 13 (8b) , 1653-1665
EORTC trial 11001: distribution of two 10B‐compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial
Boron neutron capture therapy (BNCT) provides highly targeted delivery of radiation through the limited spatial distribution of its effects. This translational research/phase I clinical trial investigates whether BNCT might be developed as a treatment option for squamous cell carcinoma of head and neck (SCCHN) relying upon preferential uptake of the two compounds, sodium mercaptoundecahydro‐closo‐dodecaborate (BSH) or L‐para‐boronophenylalanine (BPA) in the tumour. Before planned tumour resection, three patients received BSH and three patients received BPA. The 10B‐concentration in tissues and blood was measured with prompt gamma ray spectroscopy. Adverse effects from compounds did not occur. After BPA infusion the 10B‐concentration ratio of tumour/blood was 4.0 ± 1.7. 10B‐concentration ratios of tumour/normal tissue were 1.3 ± 0.5 for skin, 2.1 ± 1.2 for muscle and 1.4 ± 0.01 for mucosa. After BSH infusion the 10B‐concentration ratio of tumour/blood was 1.2 ± 0.4. 10B‐concentration ratios of tumour/normal tissue were 3.6 ± 0.6 for muscle, 2.5 ± 1.0 for lymph nodes, 1.4 ± 0.5 for skin and 1.0 ± 0.3 for mucosa. BPA and BSH deliver 10B to SCCHN to an extent that might allow effective BNCT treatment. Mucosa and skin are the most relevant organs at risk.
- 10 July 2009
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 13 (8b) , 1653-1665
Open AccessEORTC trial 11001: distribution of two 10B‐compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial
Boron neutron capture therapy (BNCT) provides highly targeted delivery of radiation through the limited spatial distribution of its effects. This translational research/phase I clinical trial investigates whether BNCT might be developed as a treatment option for squamous cell carcinoma of head and neck (SCCHN) relying upon preferential uptake of the two compounds, sodium mercaptoundecahydro‐closo‐dodecaborate (BSH) or L‐para‐boronophenylalanine (BPA) in the tumour. Before planned tumour resection, three patients received BSH and three patients received BPA. The 10B‐concentration in tissues and blood was measured with prompt gamma ray spectroscopy. Adverse effects from compounds did not occur. After BPA infusion the 10B‐concentration ratio of tumour/blood was 4.0 ± 1.7. 10B‐concentration ratios of tumour/normal tissue were 1.3 ± 0.5 for skin, 2.1 ± 1.2 for muscle and 1.4 ± 0.01 for mucosa. After BSH infusion the 10B‐concentration ratio of tumour/blood was 1.2 ± 0.4. 10B‐concentration ratios of tumour/normal tissue were 3.6 ± 0.6 for muscle, 2.5 ± 1.0 for lymph nodes, 1.4 ± 0.5 for skin and 1.0 ± 0.3 for mucosa. BPA and BSH deliver 10B to SCCHN to an extent that might allow effective BNCT treatment. Mucosa and skin are the most relevant organs at risk.
- 1 July 2009
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 67 (7-8) , S59-S62
Early clinical trial concept for boron neutron capture therapy: A critical assessment of the EORTC trial 11001
- 1 July 2009
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 67 (7-8) , S59-S62
Early clinical trial concept for boron neutron capture therapy: A critical assessment of the EORTC trial 11001
- 1 July 2009
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 67 (7-8) , S302-S305
Boron neutron capture therapy for an explanted organ: The logistical challenges
- 1 July 2009
- Published by Elsevier in Applied Radiation and Isotopes
- Vol. 67 (7-8) , S302-S305
Boron neutron capture therapy for an explanted organ: The logistical challenges
- 6 March 2009
- Vol. 55 (88) , 1951-4
Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma.
The cure or long-term survival of hilar cholangiocarcinoma patients can only be achieved after complete tumor resection. Many patients though suffer from unresectable hilar cholangiocarcinoma, and palliative treatment is therefore the only therapeutic option. In cases of unresectable bile duct cancer, intraoperative radiotherapy (IORT) is an additional option during surgery. The aim of this study was to compare the efficacy of IORT to surgery alone in patients with unresectable hilar cholangiocarcinoma. Palliative IORT (group 1) was performed on 9 patients (4 female/5 male); surgery alone (group 2) was performed in a case-matched group of 9 patients (4 female, 5 male) with unresectable hilar cholangiocarcinoma. The mean ages were 52.9 years (group 1) and 57.2 years (group 2). The two groups had comparable local tumor extension and stages of tumor disease according to UICC 6th edition. Group 1 was also compared to all 36 patients (n=36) suffering from unresectable cholangiocarcinoma treated without IORT (Group 3). The survival of patients after IORT was significantly improved compared to surgery alone in this study. The median survival time was 23.3 months (group 1) versus 9.4 months (group 2) and 5.7 month (group 3). The one year and two year actuarial survival rates are: 56% and 42% (group 1), 33% and 0% (group 2), 25% and 8% (group 3). Palliative surgery including IORT is safe for patients with unresectable hilar cholangiocarcinoma. The benefit shown by this investigation is a significant improvement of survival time after application of IORT in the palliative situation. A prospective study with randomization is needed to confirm these first results in a larger cohort.
- 6 March 2009
- Vol. 55 (88) , 1951-4
Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma.
The cure or long-term survival of hilar cholangiocarcinoma patients can only be achieved after complete tumor resection. Many patients though suffer from unresectable hilar cholangiocarcinoma, and palliative treatment is therefore the only therapeutic option. In cases of unresectable bile duct cancer, intraoperative radiotherapy (IORT) is an additional option during surgery. The aim of this study was to compare the efficacy of IORT to surgery alone in patients with unresectable hilar cholangiocarcinoma. Palliative IORT (group 1) was performed on 9 patients (4 female/5 male); surgery alone (group 2) was performed in a case-matched group of 9 patients (4 female, 5 male) with unresectable hilar cholangiocarcinoma. The mean ages were 52.9 years (group 1) and 57.2 years (group 2). The two groups had comparable local tumor extension and stages of tumor disease according to UICC 6th edition. Group 1 was also compared to all 36 patients (n=36) suffering from unresectable cholangiocarcinoma treated without IORT (Group 3). The survival of patients after IORT was significantly improved compared to surgery alone in this study. The median survival time was 23.3 months (group 1) versus 9.4 months (group 2) and 5.7 month (group 3). The one year and two year actuarial survival rates are: 56% and 42% (group 1), 33% and 0% (group 2), 25% and 8% (group 3). Palliative surgery including IORT is safe for patients with unresectable hilar cholangiocarcinoma. The benefit shown by this investigation is a significant improvement of survival time after application of IORT in the palliative situation. A prospective study with randomization is needed to confirm these first results in a larger cohort.
- 1 October 2008
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 68 (1) , 66-90
Boron analysis and boron imaging in biological materials for Boron Neutron Capture Therapy (BNCT)
- 1 October 2008
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 68 (1) , 66-90
Boron analysis and boron imaging in biological materials for Boron Neutron Capture Therapy (BNCT)
- Open Access
- 1 July 2008
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (7) , 1763-1771
Laser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs
The exact intracellular localization and distribution of molecules and elements becomes increasingly important for the development of targeted therapies and contrast agents. We show that laser postionization secondary neutral mass spectrometry (laser-SNMS) is well suited to localize particular elements and small molecules with subcellular spatial resolution applying the technique exemplary to Boron Neutron Capture Therapy (BNCT). We showed in a murine sarcoma that the drugs used for clinical BNCT, namely l-para-boronophenylalanine (700 mg/kg body weight i.p.) and sodium mercaptoundecahydro-closo-dodecaborate (200 mg/kg body weight i.p.), transport the therapeutic agent 10B into the cytoplasm and into the nucleus itself, the most sensitive area of the cell. Sodium mercaptoundecahydro-closo-dodecaborate distributes 10B homogeneously and l-para-boronophenylalanine heterogeneously. When combining laser-SNMS with prompt γ-ray analysis as a screening technique, strategies for BNCT can be elaborated to develop new drugs or to improve the use of existing drugs on scientifically based evidence. The study shows the power of laser-SNMS in the early stages of drug development, also outside BNCT. [Mol Cancer Ther 2008;7(7):1763–71]
- 1 July 2008
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 7 (7) , 1763-1771
Open AccessLaser postionization secondary neutral mass spectrometry in tissue: a powerful tool for elemental and molecular imaging in the development of targeted drugs
The exact intracellular localization and distribution of molecules and elements becomes increasingly important for the development of targeted therapies and contrast agents. We show that laser postionization secondary neutral mass spectrometry (laser-SNMS) is well suited to localize particular elements and small molecules with subcellular spatial resolution applying the technique exemplary to Boron Neutron Capture Therapy (BNCT). We showed in a murine sarcoma that the drugs used for clinical BNCT, namely l-para-boronophenylalanine (700 mg/kg body weight i.p.) and sodium mercaptoundecahydro-closo-dodecaborate (200 mg/kg body weight i.p.), transport the therapeutic agent 10B into the cytoplasm and into the nucleus itself, the most sensitive area of the cell. Sodium mercaptoundecahydro-closo-dodecaborate distributes 10B homogeneously and l-para-boronophenylalanine heterogeneously. When combining laser-SNMS with prompt γ-ray analysis as a screening technique, strategies for BNCT can be elaborated to develop new drugs or to improve the use of existing drugs on scientifically based evidence. The study shows the power of laser-SNMS in the early stages of drug development, also outside BNCT. [Mol Cancer Ther 2008;7(7):1763–71]
- Open Access
- 24 December 2007
- Published by Wiley in International Journal of Cancer
- Vol. 122 (5) , 1164-1171
Uptake of two 10B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)
Disseminated metastases of colorectal cancer in liver are incurable. The trial EORTC 11001 investigates whether autotransplantation after extracorporeal irradiation of the liver by boron neutron capture therapy (BNCT) might become a curative treatment option because of selective uptake of the compounds sodium mercaptoundecahydro‐closo‐dodecaborate (BSH) or L‐para‐boronophenylalanine (BPA). BSH (50 mg/kg bw) or BPA (100 mg/kg bw) were infused into patients who subsequently underwent resection of hepatic metastases. Blood and tissue samples were analyzed forthe 10B‐concentration with prompt gamma ray spectroscopy (PGRS). Three patients received BSH and 3 received BPA. Adverse effects from the boron carriers did not occur. For BSH, the highest 10B‐concentration was observed in liver (31.5 ± 2.7 μg/g) followed by blood (24.8 ± 4.7 μg/g) and tumor (23.2 ± 2.1 μg/g) with a mean 10B‐concentration ratio metastasis/liver of 0.72 ± 0.07. For BPA, the highest 10B‐concentration was measured in metastases (12.1 ± 2.2 μg/g) followed by liver (8.5 ± 0.5 μg/g) and blood (5.8 ± 0.8 μg/g). As BPA is transported actively into cells, viable, metabolically active cells accumulate exclusively this compound. Consequently, a model is proposed to adjust the values measured by PGRS for the proportion of viable cells to express the relevant 10B‐concentration in the tumor cells, revealing a 10B‐concentration ratio metastasis/liver of 6.8 ± 1.7. In conclusion, BSH is not suitable as 10B‐carrier in liver metastases as the 10B‐concentration in liver was higher compared to metastasis. BPA accumulates in hepatic metastases to an extent that allows for extracorporeal irradiation of the liver with BNCT.
- 24 December 2007
- Published by Wiley in International Journal of Cancer
- Vol. 122 (5) , 1164-1171
Open AccessUptake of two 10B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)
Disseminated metastases of colorectal cancer in liver are incurable. The trial EORTC 11001 investigates whether autotransplantation after extracorporeal irradiation of the liver by boron neutron capture therapy (BNCT) might become a curative treatment option because of selective uptake of the compounds sodium mercaptoundecahydro‐closo‐dodecaborate (BSH) or L‐para‐boronophenylalanine (BPA). BSH (50 mg/kg bw) or BPA (100 mg/kg bw) were infused into patients who subsequently underwent resection of hepatic metastases. Blood and tissue samples were analyzed forthe 10B‐concentration with prompt gamma ray spectroscopy (PGRS). Three patients received BSH and 3 received BPA. Adverse effects from the boron carriers did not occur. For BSH, the highest 10B‐concentration was observed in liver (31.5 ± 2.7 μg/g) followed by blood (24.8 ± 4.7 μg/g) and tumor (23.2 ± 2.1 μg/g) with a mean 10B‐concentration ratio metastasis/liver of 0.72 ± 0.07. For BPA, the highest 10B‐concentration was measured in metastases (12.1 ± 2.2 μg/g) followed by liver (8.5 ± 0.5 μg/g) and blood (5.8 ± 0.8 μg/g). As BPA is transported actively into cells, viable, metabolically active cells accumulate exclusively this compound. Consequently, a model is proposed to adjust the values measured by PGRS for the proportion of viable cells to express the relevant 10B‐concentration in the tumor cells, revealing a 10B‐concentration ratio metastasis/liver of 6.8 ± 1.7. In conclusion, BSH is not suitable as 10B‐carrier in liver metastases as the 10B‐concentration in liver was higher compared to metastasis. BPA accumulates in hepatic metastases to an extent that allows for extracorporeal irradiation of the liver with BNCT.